BIOPHYTIS to Host Key Opinion Leader Meeting on the Biology of Aging and its Application in Neuromuscular Diseases
November 27, 2018 12:00 ET
|
BIOPHYTIS SA
PARIS, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specializing in the development of drug candidates to treat the disabilities...
BIOPHYTIS : Interim Results 2018 and Perspective on Activity
October 22, 2018 13:56 ET
|
BIOPHYTIS SA
PARIS, Oct. 22, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to fight age-related degenerative...
BIOPHYTIS Obtains a €10 Million Loan With Kreos Capital
September 13, 2018 12:00 ET
|
BIOPHYTIS SA
The funding will serve for the development of BIOPHYTIS Inc. in Boston and the preparation of MYODA clinical program in Duchenne myopathy PARIS, Sept. 13, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS...
BIOPHYTIS Provides Enrollment Update in Its Phase 2b SARA-OBS and SARA-INT Studies of Sarconeos in Sarcopenia
September 04, 2018 01:30 ET
|
BIOPHYTIS SA
Over 200 patients recruited in the SARA-OBS study with the majority of patients enrolled from the U.S. and Belgium 60 patients ready to enter the SARA-INT trial PARIS, Sept. 04, 2018 (GLOBE...
BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia
May 24, 2018 12:00 ET
|
BIOPHYTIS SA
Preliminary results expected in Q3 2019 PARIS, May 24, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug...
BIOPHYTIS Receives Orphan Drug Designation in the United States for Sarconeos in Duchenne Muscular Dystrophy (DMD)
May 15, 2018 14:22 ET
|
BIOPHYTIS SA
PARIS, May 15, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related degenerative...
BIOPHYTIS: 2017 Full Year Results
March 28, 2018 08:00 ET
|
BIOPHYTIS SA
Launch and progress in the SARA-OBS observational clinical study in the United States, Belgium, France, and Italy;Agencies’ authorizations of SARA-INT phase 2b interventional clinical study in the...
BIOPHYTIS files for Orphan Drug Designation for Sarconeos in Duchenne Muscular Dystrophy (DMD)
March 20, 2018 15:36 ET
|
BIOPHYTIS SA
Presentation of MYODA: a new clinical program in the treatment of Duchenne Muscular Dystrophy PARIS, March 20, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology...
BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami
March 01, 2018 02:00 ET
|
BIOPHYTIS SA
Additional data confirm the relevance of the protocol and the compound in the clinical study SARA-INT phase 2B PARIS, March 01, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a...
BIOPHYTIS to Participate in Corporate Access Event in San Francisco, January 8 - 10, 2018
December 19, 2017 01:45 ET
|
BIOPHYTIS SA
PARIS, Dec. 19, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, today...